Style | Citing Format |
---|---|
MLA | Norooznezhad AH, et al.. "Treatment of Persistent Chemotherapy-Induced Hair Loss (Alopecia) With Human Mesenchymal Stromal Cells Exosome Enriched Extracellular Vesicles: A Case Report." Heliyon, vol. 9, no. 4, 2023, pp. -. |
APA | Norooznezhad AH, Yarani R, Payandeh M, Hoseinkhani Z, Mahmoudi H, Kiani S, Mansouri K (2023). Treatment of Persistent Chemotherapy-Induced Hair Loss (Alopecia) With Human Mesenchymal Stromal Cells Exosome Enriched Extracellular Vesicles: A Case Report. Heliyon, 9(4), -. |
Chicago | Norooznezhad AH, Yarani R, Payandeh M, Hoseinkhani Z, Mahmoudi H, Kiani S, Mansouri K. "Treatment of Persistent Chemotherapy-Induced Hair Loss (Alopecia) With Human Mesenchymal Stromal Cells Exosome Enriched Extracellular Vesicles: A Case Report." Heliyon 9, no. 4 (2023): -. |
Harvard | Norooznezhad AH et al. (2023) 'Treatment of Persistent Chemotherapy-Induced Hair Loss (Alopecia) With Human Mesenchymal Stromal Cells Exosome Enriched Extracellular Vesicles: A Case Report', Heliyon, 9(4), pp. -. |
Vancouver | Norooznezhad AH, Yarani R, Payandeh M, Hoseinkhani Z, Mahmoudi H, Kiani S, et al.. Treatment of Persistent Chemotherapy-Induced Hair Loss (Alopecia) With Human Mesenchymal Stromal Cells Exosome Enriched Extracellular Vesicles: A Case Report. Heliyon. 2023;9(4):-. |
BibTex | @article{ author = {Norooznezhad AH and Yarani R and Payandeh M and Hoseinkhani Z and Mahmoudi H and Kiani S and Mansouri K}, title = {Treatment of Persistent Chemotherapy-Induced Hair Loss (Alopecia) With Human Mesenchymal Stromal Cells Exosome Enriched Extracellular Vesicles: A Case Report}, journal = {Heliyon}, volume = {9}, number = {4}, pages = {-}, year = {2023} } |
RIS | TY - JOUR AU - Norooznezhad AH AU - Yarani R AU - Payandeh M AU - Hoseinkhani Z AU - Mahmoudi H AU - Kiani S AU - Mansouri K TI - Treatment of Persistent Chemotherapy-Induced Hair Loss (Alopecia) With Human Mesenchymal Stromal Cells Exosome Enriched Extracellular Vesicles: A Case Report JO - Heliyon VL - 9 IS - 4 SP - EP - PY - 2023 ER - |